Compare Cintas Corporation (CTAS) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cintas Corporation vs GeneDx Holdings Corp — how do they compare? Cintas Corporation trades at $204.37 (market cap $82.15B), while GeneDx Holdings Corp trades at $81.93 (market cap $2.44B). The key difference: Cintas Corporation is far larger — about 33.7× GeneDx Holdings Corp's market cap, and Cintas Corporation pays a 1.01% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| CTAS | WGS | |
|---|---|---|
Market Cap | $82.15B | $2.44B |
Sector | Industrials | Technology |
52-Week High | $225.10 | $167.51 |
52-Week Low | $163.55 | $34.51 |
Enterprise Value | $84.56B | $2.48B |
Dividend Yield | 1.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cintas (CTAS) trades at $204.86, up 1.06% on the day, with a bullish technical signal and recent earnings beats driving positive momentum. The company reported strong Q2 2026 EPS of $1.29, exceeding expectations, and maintains robust fundamentals with a 17.75% net income margin and 40.59% ROE. Revenue growth is steady, reaching $10.34B in 2025, supported by consistent profitability and a dividend payout.
The outlook is positive, with a consensus price target of $225.83 implying ~10% upside, though high valuation ratios (P/E 41.81) and competitive pressures pose risks. Institutional interest is strong, with recent upgrades, but investors should monitor debt levels and economic sensitivity.
GeneDx Holdings Corp (WGS) trades at $82.07, up 5.38% in the past 24 hours, with technical indicators showing a bullish trend. The stock beat Q2 2026 EPS estimates but reported negative net income margins. Recent news highlights product expansion and institutional buying interest, though class-action lawsuits pose near-term sentiment risks.
Outlook is mixed: strong analyst buy ratings (90.9%) and a $79.25 consensus target suggest upside, but high valuation multiples and persistent losses require caution. Key risks include profitability challenges and legal overhangs, while revenue growth and market positioning offer long-term potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cintas Corporation
In its core uniform and facility services unit (78% of sales), Cintas provides uniform rental programs to businesses across the size spectrum, mostly in North America. The firm is by far the largest provider in the industry. Facilities products generally include the rental and sale of entrance mat, mops, shop towels, hand sanitizers, and restroom supplies. Cintas also runs a first aid and safety services business (11% of sales), a fire protection services business (7% of sales), and a uniform direct sales business (4% of sales).
Read more on CTAS →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
